Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.82USD
22 Jul 2019
Change (% chg)

-- (--)
Prev Close
$42.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,506,331
52-wk High
$46.46
52-wk Low
$37.14

Latest Key Developments (Source: Significant Developments)

Rising Pharmaceuticals Announces The U.S. Launch Of A Generic Version Of Pregabalin Capsules
Friday, 19 Jul 2019 

July 19 (Reuters) - Rising Pharmaceuticals::RISING PHARMACEUTICALS - ANNOUNCED U.S. LAUNCH OF GENERIC VERSION OF LYRICA, (PREGABALIN) CAPSULES, IN ALL 8 COMMERCIALLY AVAILABLE STRENGTHS.  Full Article

Health Canada Says Pfizer Confirms EpiPen 0.3 Mg Supply Is Currently Available And Continues To Be Shipped
Friday, 19 Jul 2019 

July 19 (Reuters) - Health Canada::HEALTH CANADA - PFIZER HAS CONFIRMED THAT EPIPEN 0.3 MG SUPPLY IS CURRENTLY AVAILABLE AND CONTINUES TO BE SHIPPED.HEALTH CANADA - PFIZER IS REPORTING THAT IT ESTIMATES EPIPEN 0.3 MG SUPPLY ISSUE WILL BE FULLY RESOLVED IN EARLY OCTOBER 2019.HEALTH CANADA - PFIZER INDICATED THAT IT HAS BEGUN MANAGING DISTRIBUTION OF EXISTING EPIPEN 0.3 MG SUPPLY TO HELP ENSURE CONSISTENT ACCESS BY PATIENTS.  Full Article

Statement From Health Canada On The Supply Of EpiPen 0.3 Mg Auto-Injectors
Friday, 19 Jul 2019 

July 19 (Reuters) - Health Canada::STATEMENT FROM HEALTH CANADA ON THE SUPPLY OF EPIPEN 0.3 MG AUTO-INJECTORS.HEALTH CANADA - EPIPEN JR (0.15 MG) IS NOT AFFECTED BY SHORTAGE.HEALTH CANADA - AWARE THAT PFIZER CANADA IS REPORTING THAT A SHORTAGE OF 0.3 MG FORMAT EPIPEN AUTO-INJECTOR MAY LEAD TO TEMPORARY SUPPLY CONSTRAINTS.HEALTH CANADA - ANTICIPATES THERE WILL BE ADEQUATE SUPPLY OF EPINEPHRINE AUTO-INJECTORS IN CANADA TO MEET NEEDS OF CANADIANS OVER COMING MONTHS.HEALTH CANADA - INTERIM ORDER THAT FACILITATES IMPORT OF AN ALTERNATIVE EPINEPHRINE AUTO-INJECTOR, AUVI-Q, REMAINS IN EFFECT.HEALTH CANADA - AUVI-Q REMAINS AVAILABLE FOR CANADIANS TO ACCESS.HEALTH CANADA - PFIZER REPORTED SHORTAGE ON JULY 16, INFORMED HEALTH CANADA THAT IT CONTINUES TO SHIP PRODUCT TO CANADA.  Full Article

Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES INITIATES PHASE 1/2 TRIAL OF TELAGLENASTAT IN COMBINATION WITH PFIZER’S CDK4/6 INHIBITOR PALBOCICLIB.CALITHERA BIOSCIENCES - ANNOUNCED TREATMENT OF FIRST PATIENT IN PHASE 1/2 TRIAL OF GLUTAMINASE INHIBITOR TELAGLENASTAT WITH PFIZER'S IBRANCE.CALITHERA BIOSCIENCES INC - AS PART OF AGREEMENT, PFIZER IS PROVIDING PALBOCICLIB AND TALAZOPARIB, AS WELL AS FINANCIAL SUPPORT.  Full Article

Pfizer Announces Positive Top-Line Results From Phase 4 Study Of Crisaborole Ointment
Monday, 1 Jul 2019 

July 1 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 4 STUDY OF CRISABOROLE OINTMENT, 2%, IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS.PFIZER INC - SAFETY PROFILE CONSISTENT WITH PREVIOUS CLINICAL TRIAL EXPERIENCE.PFIZER INC - DATA SHOW CRISABOROLE OINTMENT, 2%, A STEROID-FREE TOPICAL TREATMENT, WAS WELL-TOLERATED OVER 4-WEEK TREATMENT PERIOD.PFIZER INC - SAFETY PROFILE CONSISTENT WITH PREVIOUS CLINICAL TRIAL EXPERIENCE.PFIZER INC - STUDY DATA SHOW CRISABOROLE OINTMENT, 2%, A STEROID-FREE TOPICAL TREATMENT, WAS WELL-TOLERATED OVER 4-WEEK TREATMENT PERIOD.  Full Article

Pfizer Announces Results From Phase 3 Trial Of Revatio (Sildenafil Citrate) In Newborns With Persistent Pulmonary Hypertension
Friday, 28 Jun 2019 

June 28 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF REVATIO (SILDENAFIL CITRATE) IN NEWBORNS WITH PERSISTENT PULMONARY HYPERTENSION.PFIZER INC - PHASE 3 STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT.PFIZER - TREATMENT WITH IV SILDENAFIL WHEN ADDED TO INO DID NOT RESULT IN STATISTICALLY SIGNIFICANT REDUCTION IN TREATMENT FAILURE RATE OR TIME ON INO.  Full Article

Pfizer Sets Quarterly Cash Dividend Of $0.36 Per Share
Thursday, 27 Jun 2019 

June 27 (Reuters) - Pfizer Inc ::SETS QUARTERLY CASH DIVIDEND OF $0.36PER SHARE.  Full Article

Biomarin Earns Milestone Payments From Pfizer
Friday, 21 Jun 2019 

June 21 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN EARNS MILESTONE PAYMENTS FROM PFIZER FOR TALZENNA® (TALAZOPARIB) FOR METASTATIC BREAST CANCER PATIENTS WITH AN INHERITED BRCA MUTATION.BIOMARIN PHARMACEUTICAL INC - EUROPEAN COMMISSION APPROVAL TRIGGERS $15 MILLION PAYMENT.BIOMARIN PHARMACEUTICAL INC - BIOMARIN ENTITLED TO EARN MID-SINGLE DIGIT ROYALTIES ON FUTURE SALES.BIOMARIN PHARMACEUTICAL INC - COMPANY EARNED A $15 MILLION MILESTONE PAYMENT FROM PFIZER.BIOMARIN PHARMACEUTICAL INC - $15 MILLION MILESTONE PAYMENT WAS TRIGGERED BY EUROPEAN COMMISSION APPROVAL OF TALZENNA.  Full Article

Pfizer To Acquire Array Biopharma For $48/share In Cash
Monday, 17 Jun 2019 

June 17 (Reuters) - Array Biopharma Inc ::PFIZER TO ACQUIRE ARRAY BIOPHARMA.ARRAY BIOPHARMA INC - DEAL FOR $48 PER SHARE IN CASH.ARRAY BIOPHARMA INC - DEAL FOR TOTAL ENTERPRISE VALUE OF APPROXIMATELY $11.4 BILLION.ARRAY BIOPHARMA INC - TRANSACTION VALUED AT $48 PER ARRAY SHARE IN CASH, FOR A TOTAL ENTERPRISE VALUE OF APPROXIMATELY $11.4 BILLION.ARRAY BIOPHARMA INC - PFIZER EXPECTS TO FINANCE MAJORITY OF DEAL WITH DEBT AND BALANCE WITH EXISTING CASH.ARRAY BIOPHARMA INC - BOARDS OF DIRECTORS OF BOTH COMPANIES HAVE APPROVED MERGER.ARRAY BIOPHARMA INC - TRANSACTION IS EXPECTED TO BE DILUTIVE TO PFIZER'S ADJUSTED DILUTED EPS BY $0.04 -$0.05 IN 2019.ARRAY BIOPHARMA INC - UPON CLOSE OF TRANSACTION, ARRAY'S EMPLOYEES WILL JOIN PFIZER.ARRAY BIOPHARMA INC - DEAL EXPECTED TO BE DILUTIVE TO PFIZER'S ADJUSTED DILUTED EPS BY $0.04 -$0.05 IN 2020, NEUTRAL IN 2021.ARRAY BIOPHARMA INC - PFIZER EXPECTS TO COMPLETE ACQUISITION IN SECOND HALF OF 2019.ARRAY BIOPHARMA INC - TRANSACTION IS EXPECTED TO BE ACCRETIVE TO PFIZER BEGINNING IN 2022.ARRAY BIOPHARMA INC - PLANS TO MAINTAIN PRODUCTIVE RESEARCH UNIT IN BOULDER TO COMPLEMENT PFIZER'S RESEARCH HUBS.ARRAY BIOPHARMA - AGREEMENT CONTEMPLATES THAT PFIZER WILL ACQUIRE ANY SHARES OF ARRAY THAT ARE NOT TENDERED INTO OFFER THROUGH A SECOND-STEP MERGER.ARRAY BIOPHARMA INC - PFIZER WILL PROVIDE ANY UPDATES TO ITS CURRENT 2019 GUIDANCE IN CONJUNCTION WITH ITS Q3 2019 EARNINGS RELEASE.  Full Article

Pfizer Announces Results From Xeljanz XR Oral Shift Study, The First Phase 3B/4 Study To Evaluate Methotrexate Withdrawal With A Jak Inhibitor
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES RESULTS FROM XELJANZ® XR (TOFACITINIB) ORAL SHIFT STUDY, THE FIRST PHASE 3B/4 STUDY TO EVALUATE METHOTREXATE WITHDRAWAL WITH A JAK INHIBITOR.PFIZER INC - STUDY DEMONSTRATED NON-INFERIORITY OF MTX WITHDRAWAL WITH XELJANZ XR 11 MG QD VERSUS XELJANZ XR 11 MG QD PLUS MTX.PFIZER INC - SAFETY FINDINGS IN ORAL SHIFT INCLUDE MOST FREQUENTLY REPORTED ADVERSE EVENTS (AES) FOR EACH STUDY GROUP.PFIZER INC - IN DOUBLE-BLIND TREATMENT PERIOD, THERE WERE TWO DEATHS REPORTED IN XELJANZ XR PLUS MTX TREATMENT GROUP..  Full Article

UPDATE 2-Health Canada to keep importing Kaleo's epinephrine shot amid shortages

July 19 The Canadian health regulator said on Friday it would keep importing U.S.-based Kaleo Inc's epinephrine auto-injectors and expects adequate supply of the devices in the country over the coming months.